At what ages should adolescents receive the MCV4 vaccination?

The correct answer is centered around the recommended vaccination schedule for the meningococcal conjugate vaccine (MCV4), which is vital for protecting against serogroups A, C, W, and Y of Neisseria meningitidis. The Advisory Committee on Immunization Practices (ACIP) recommends that adolescents receive a primary dose of MCV4 at 11 or 12 years of age. This age is chosen to ensure that adolescents are immunized before they enter high school, where they may be at higher risk for meningococcal disease.

Additionally, a booster dose is recommended at 16 years of age. This booster is crucial because immunity provided by the first dose can wane over time, and a booster dose ensures continued protection during the late teenage years when the risk is typically highest. By administering the vaccine at these key ages, health professionals can significantly reduce the incidence of meningococcal disease in adolescents.

The other suggested options do not align with current vaccination guidelines, either by recommending doses at too early an age or by suggesting incorrect booster timings. Thus, the recommended schedule of a primary dose at 11 or 12 years followed by a booster at 16 optimally supports immunization strategies against meningococcal